Two new drugs approved, offering patients new treatment options
Recently, the National Medical Products Administration conditionally approved, through the priority review and approval procedure, the application submitted by Jiangsu Hengrui Pharmaceuticals Co., Ltd.Zemeisotase Tablets, a Class 1 innovative drug (brand name: Aireijing)declared by Boehringer Ingelheim International GmbHZongaitini Tablets, a Class 1 innovative drug (brand name: Shenghetu)Listing.
This drug is indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one prior systemic therapy.
This drug, as a single agent, is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy.
Two drugs launched on the market
was provided to the patient
New treatment options
Source: National Medical Products Administration, Chongqing Medical Products Administration official account
First review: Wang Yao | Second review: Teng Chunyan | Final review: Liu Bin